SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation that cannabis rescheduling may be imminent, with some anticipating a resulting sector-wide surge. The community is actively discussing the potential impact of a presidential executive order on tax relief and banking access. Some investors are optimistic about a short squeeze, while others remain cautious due to the company's history.

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending due to speculation of a potential short squeeze, driven by its low float and recent AI deal. Community members are actively discussing key breakout levels and anticipating a significant price surge. The stock is drawing comparisons to other low-float runners, fueling excitement around potential for substantial gains.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power ($SMR) is trending due to discussions around its potential role in powering AI data centers and a recent agreement with the Tennessee Valley Authority, though concerns persist around its financial performance and Fluor's stake monetization. The community is weighing the company's regulatory advantages and the increasing need for SMR technology against factors like potential share dilution and competition in the sector. Recent analyst target price reductions and overall nuclear sector bearishness may also be contributing to the conversation.

Aurora Cannabis, Inc. engages in the production, distribution, and sale of cannabis and cannabis-derivative products. It operates through the Cannabis and Plant Propagation segments. The company was founded by Terry Booth and Steve Dobler on December 21, 2006 and is headquartered in Edmonton, Canada.

Aurora Cannabis Inc

Aurora Cannabis is trending amidst reports that Trump may consider rescheduling marijuana, potentially affecting taxation and medical access. The community is discussing the potential impact of this policy change and whether it will be a "sell the news" event. Scanners continue to light up as cannabis tickers show increased interest in response to the news.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending due to positive reactions to its AI and autonomy day, with discussions focusing on the potential of its new in-house AI chip and self-driving capabilities. The community is weighing the company's advancements against competitors like Tesla and speculating on a possible short squeeze. Some investors are concerned about cash burn and the timeline for seeing returns on these new technologies.

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

BridgeBio Pharma Inc

BBIO is trending due to analyst upgrades and positive sentiment around the launch of Attruby, with the community actively discussing its potential to outperform competitors and the impact of upcoming Phase 3 readouts. Community members are weighing its growth potential in the context of a potentially undervalued biotech, while also considering the potential for acquisition by a major pharmaceutical company. Actionable trade alerts highlight possible entry and exit points based on technical analysis.

Gunz

Gunz ($GUN) is trending amid community excitement about potential breakouts and large whale buys, with some eyeing a return to all-time highs. The token is also getting attention due to its association with the Off The Grid (OTG) web3 game on the Avalanche network ($AVAX), leading to discussions about its tokenomics and potential for quick gains.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending as speculation mounts around potential federal cannabis policy changes, specifically regarding rescheduling. Community chatter revolves around whether an executive order will materialize, with some anticipating a significant sector-wide surge while others remain cautiously optimistic due to past disappointments. The ETF's exposure to US cannabis companies positions it to potentially benefit from any regulatory easing.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending due to the upcoming launch of BlueBird 6, marking a significant step towards a launch cadence of approximately every 45 days in 2026; this represents a shift from concept to operational deployment. The community is buzzing about the potential for a Starlink competitor and the company's long-term prospects, with some highlighting the high short interest and potential for a squeeze.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending amid a leadership transition as the CEO steps down, sparking speculation about a strategy shift. A recent earnings beat and a substantial share buyback program are fueling bullish sentiment, although some express concerns about margin pressure and softness in the Americas. Community members are actively discussing the potential for a turnaround, especially with the brand's strong international growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Super Micro's headwinds stemming from AI-bubble fears contrast with improving compliance, new Nvidia-powered products, and a more reasonable valuation.</li><li>Moderna continues to struggle post-pandemic, with weak fundamentals, no new blockbusters, and higher regulatory scrutiny weighing on its pipeline.</li><li>Analysts see greater upside for Super Micro than Moderna, while retail sentiment remains cautious toward both stocks.</li></ul>Investing in heavily shorted stocks isn't for the faint-hearted. While they can offer meaningful upside, that potential comes with heightened volatility and elevated risk. More often than not, they are shorted for legitimate reasons. But if the sentiment flips, these stocks can deliver explosive gains. The most-shorted S&amp;P 500 list currently includes two names that won't surprise many investors.&nbsp;Moderna — the biopharma that, along with Pfizer, led the COVID-19 vaccine race — rode a historic wave of demand during the pandemic. But as the outbreak faded and vaccine sales collapsed, the company's fundamentals have come under pressure despite efforts to sustain momentum with second-generation and combination shots. The company is still searching for its next blockbuster therapy.Super Micro Computer, Inc. (SMCI), which rode the artificial intelligence mania, selling AI servers, was once touted as a promising opportunity. The company, however, ran into rough weather in 2024 amid accusations of accounting issues, delays in filing of financial reports, and&nbsp;attacks from short-sellers.Since peaking at $122.90 on March 8, 2024, the stock has traded broadly downward for the rest of the year. Super Micro's addition to the S&amp;P 500 provided a boost, but it failed to reignite the uptrend. Notably, the company was removed from the Nasdaq 100 just five months after its inclusion in the tech index.<h2 class="st-heading-2">Stock Returns This Year</h2>As Super Micro became compliant with the listing requirements for timely quarterly reporting, buyers returned to the stock. The<a href="https://stocktwits.com/symbol/SMCI">&nbsp;SMCI stock</a> also benefited from the company's new offerings involving Nvidia's newest high-performance chips and its positive long-term outlook. Its near-term underperformance raised concerns among investors.&nbsp;After rising through the first quarter, Super Micro's stock pulled back and hit a low in mid-November and has been consolidating since.<a href="https://stocktwits.com/symbol/MRNA">Moderna's stock</a> was on a steady downward trajectory this year, barring occasional consolidation moves.<img src="https://news.stocktwits-cdn.com/MRNA_SMCI_stock_returns_png_dd55f22501.webp" alt="MRNA-SMCI stock returns.png">Source: Koyfin<h2 class="st-heading-2">Elevated Short Bets&nbsp;</h2>According to Koyfin, the short interest for Super Micro peaked in April (19.60%) before reducing to 14.70% currently. Moderna's short interest, though off its May peak of 17.40%, has declined by less than one percentage point.<img src="https://news.stocktwits-cdn.com/MRNA_SMCI_short_interest_png_9af30dca45.webp" alt="MRNA-SMCI-short interest.png">Source: Koyfin<h2 class="st-heading-2">Time To Revisit?</h2>Super Micro now trades at a relatively reasonable valuation (in terms of the forward price-earnings (P/E) multiple versus the tech sector and its peak multiple).<img src="https://news.stocktwits-cdn.com/SMCI_Forward_PE_png_d98fc94770.webp" alt="SMCI_Forward_PE.png">Source: Fiscal.aiModerna, on the other hand, trades at a much higher price-to-sales (P/S) multiple than it did last July. Since Moderna is projected to report losses over the next year, the P/E ratio isn't applicable.<img src="https://news.stocktwits-cdn.com/MRNA_Forward_PS_png_794682e423.webp" alt="MRNA_Forward_PS.png">Source: Fiscal.aiAccording to Koyfin-compiled consensus analysts' stock price targets for the companies,&nbsp; estimates, Super Micro has an upside potential of 39% versus 23% for Moderna.&nbsp;Super Micro has an equal share of analysts who are bullish and neutral on the stock. Meanwhile, more analysts are on the sidelines of Moderna (15 of the 22 analysts covering the stock).On Stocktwits, retail traders are 'bearish' on Super Micro as of early Thursday, while Moderna elicited 'neutral' sentiment.For Super Micro, simmering AI bubble fears could remain an overhang on the stock. Still, if the company can execute its plans and leverage its partnership with Nvidia, the stock could see a reversal in fortunes. Moderna, meanwhile, remains a "show-me" story as it has to prove the mettle of the rest of its pipeline. Moderna also faces regulatory uncertainty as the FDA applies heightened scrutiny to new vaccines and therapeutics, adding another layer of risk to its pipeline.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:<a href="https://stocktwits.com/news-articles/markets/equity/powell-didn-t-surprise-how-retail-traders-are-positioning-after-fed-s-rate-cut/cLIx7TYREn2">&nbsp;Powell Didn't Surprise — But Markets Might: How Retail Traders Are Positioning After Fed's Rate Cut</a>

 Traders work on the floor of the New York Stock Exchange (NYSE) on December 02, 2025 in New York City. After losing over 400 points on the first day of December, the market began to recover with the Dow up over 120 points in morning trading. 

Moderna And Super Micro Top S&P 500 Short Interest List — Are They Ripe For A Squeeze?

Investors remain divided on Moderna and Super Micro as heavy short interest reflects skepticism, yet recent catalysts suggest both names could still deliver unpredictable, sentiment-driven swings.

Equity

Inside the Recent Strength in Biotech ETFs 

Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.



Biotech ETFs Hovering Around a 52-Week: Here's Why 

Biotech is back! Regulatory tailwinds, cheaper valuations, and Fed cut hopes are boosting ETFs like XBI and IBB. Is the rebound just starting?

Biotech ETFs Bounce Back in 2025: Here's Why  

Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.

Health and Human Services Secretary Robert F. Kennedy Jr. will appear before the Senate Finance Committee on Sept. 4 to discuss U.S. President Donald Trump’s healthcare agenda.Chairman Mike Crapo said the hearing will focus on “the Department of Health and Human Services’ Make America Healthy Again actions to date and plans moving forward,” Reuters&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/kennedy-testify-before-senate-panel-health-agenda-2025-08-28/">reported</a>.The session comes after the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cdc-chief-susan-monarez-pushed-out-after-weeks-on-job-as-rfk-jr-overhauls-agency-she-s-fighting-back/chsCsP4Rdli">White House dismissed CDC Director Susan Monarez</a> on Wednesday, less than a month into her tenure. An associate said Monarez was fired after resisting vaccine policy changes advanced by Kennedy that she believed contradicted scientific evidence.&nbsp;Hours later, three senior officials — Chief Medical Officer Debra Houry, National Center for Immunization and Respiratory Diseases Director Demetre Daskalakis, and National Center for Emerging and Zoonotic Infectious Diseases Director Daniel Jernigan — resigned and were&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/litigation/fired-cdc-director-clashed-with-kennedy-on-vaccine-policy-2025-08-28/">reportedly</a> escorted from the Atlanta campus.&nbsp;CDC staff, many wearing green shirts and ribbons as a sign of support, applauded them as they departed.Richard Besser, former acting CDC director, said Monarez told him she would not take any action that was illegal or “flew in the face of science,” and she refused to dismiss her leadership team without cause.&nbsp;The three departing officials said they resigned over anti-vaccine policies and misinformation promoted by Kennedy and his team. Daskalakis said, “I’m a doctor. I took the Hippocratic oath that said, ‘First, do no harm.’ I believe harm is going to happen, and so I can’t be a part of it.”Since taking office this year, Kennedy has fired the CDC’s vaccine advisory panel and replaced it with anti-vaccine activists and other advisers.&nbsp;He has made false claims about vaccines and launched an investigation into autism rates that he has linked, without evidence, to “environmental toxins.”&nbsp;The CDC has since dropped its recommendation that pregnant women be vaccinated against COVID and narrowed its guidance for children with health complications.White House spokeswoman Karoline Leavitt said Monarez was dismissed because she did not align with the president’s mission. “She said she would [resign], and then she said she wouldn’t, so the president fired her,” Leavitt said.&nbsp;Kennedy declined to comment on the specifics of the departures but told&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.foxnews.com/media/rfk-jr-warns-cdc-in-trouble-promises-fixes-director-refuses-step-down">Fox News</a>, “The agency is in trouble, and we need to fix it and we are fixing it. And it may be that some people should not be working there anymore.”&nbsp;Deputy HHS Secretary Jim O’Neill was named interim director of the CDC.Monarez’s dismissal is one of several recent moves by Trump to remove Senate-confirmed officials, including Federal Reserve Governor Lisa Cook and Surface Transportation Board member Robert Primus.On Stocktwits, retail sentiment was ‘bearish’ with ‘low’ message volume for both the iShares Biotechnology ETF (IBB) and the Health Care Select Sector SPDR Fund (XLV).While&nbsp;<a href="https://stocktwits.com/symbol/XLV">XLV</a> has been flat so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/IBB">IBB</a> has risen 4.6% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Health and Human Services Secretary Robert F. Kennedy Jr. speaks during a cabinet meeting with U.S. President Donald Trump on August 26, 2025 in Washington, DC. (Photo by Chip Somodevilla/Getty Images)

CDC Turmoil Escalates: Kennedy To Testify In Senate After Director Fired, Senior Officials Quit

The White House's move to oust Susan Monarez and the wave of senior CDC resignations have spotlighted deep divisions over vaccine policy and raised fresh questions about the administration’s healthcare agenda.

U.S. Centers for Disease Control and Prevention Director Susan Monarez has left the agency less than a month after being sworn in, amid the resignation of four senior officials&nbsp;who also resigned over vaccine policy tensions.Monarez’s attorneys said she is challenging her ouster, accusing HHS Secretary Robert F. Kennedy Jr. of targeting her for rejecting “unscientific directives,” Reuters&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-cdc-chief-exits-after-weeks-role-three-top-officials-resign-2025-08-27/">reported</a>.&nbsp;“Dr. Monarez has neither resigned nor received notification from the White House that she has been fired, and as a person of integrity and devoted to science, she will not resign,” lawyers Mark S. Zaid and Abbe David Lowell said.The U.S. Department of Health and Human Services' account on X shared a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/HHSGov/status/1960818490614415869">post</a> about Monarez's exit, saying: "We thank her for her dedicated service to the American people. @SecKennedy has full confidence in his team at @CDCgov who will continue to be vigilant in protecting Americans against infectious diseases at home and abroad."CDC Chief Medical Officer Debra Houry and Immunization Center Director Demetre Daskalakis have resigned, citing the rise in health misinformation, attacks on science, and budget cuts.&nbsp;Infectious Diseases Director Daniel Jernigan and Public Health Data Director Jen Layden also stepped down. Houry wrote that overstated risks and misinformation have fueled record measles cases and even a violent attack on the CDC.The White House’s 2026 budget proposed cutting CDC funding by $3.6 billion, while Kennedy had already eliminated 2,400 jobs and rehired 700. Daskalakis said he could not serve amid the “ongoing weaponizing of public health.”The CDC has faced mounting strain under Kennedy, including a shooting at its Atlanta headquarters. Former CDC official Fiona Havers called the latest resignations “devastating,” saying the departed leaders had shielded scientists from political attacks.Kennedy has rolled back vaccine policies, withdrawing COVID shot recommendations for children and pregnant women, and firing all members of the CDC vaccine advisory panel in June, replacing them with hand-picked advisers, including vaccine skeptics.&nbsp;On Wednesday, he announced further changes to COVID-19 vaccine eligibility and stated that autism policy announcements are expected in September.Monarez, a federal scientist, was confirmed on July 29 after being nominated by U.S. President Trump and sworn in by Kennedy on July 31. She succeeded Trump’s withdrawn pick, former congressman and vaccine critic Dave Weldon.&nbsp;On Stocktwits, retail sentiment was bearish for both the iShares Biotechnology ETF (IBB) with normal message volume, and the Health Care Select Sector SPDR Fund (XLV) with low message volume.So far this year,&nbsp;<a href="https://stocktwits.com/symbol/IBB">IBB</a> has gained 4.9%, while&nbsp;<a href="https://stocktwits.com/symbol/XLV">XLV</a> has increased by 0.4%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Monarez is a health scientist with a Ph.D. in microbiology and immunology who previously served as the Deputy Director of the Advanced Research Projects Agency for Health. (Photo by Kayla Bartkowski/Getty Images)

CDC Chief Susan Monarez Pushed Out After Weeks On Job As RFK Jr. Overhauls Agency — She’s Fighting Back

The sudden leadership shake-up at the CDC deepens turmoil inside the agency, where multiple senior officials have also resigned over vaccine policy disputes with Health Secretary Robert F. Kennedy Jr.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Should You Invest in the iShares Biotechnology ETF (IBB)?

US Food and Drug Administration Commissioner Marty Makary said he’s “taking a hard look” at whether Sarepta Therapeutics’ gene therapy, Elevidys, should remain on the market, following recent patient deaths involving the treatment.&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="http://stockwits.com/symbol/SRPT">Sarepta’s stock</a> plummeted more than 26% in midday trade on Friday. However, on Stocktwits, retail sentiment around the company remained in ‘extremely bullish’ territory amid ‘extremely high’ levels of chatter.A separate&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-request-sarepta-stop-all-shipments-gene-therapy-elevidys-source-says-2025-07-18/#:~:text=The%20FDA's%20request%20follows%20the,condition%20called%20Duchenne%20muscular%20dystrophy.">report</a> by Reuters said that the FDA plans to request Sarepta to stop all shipments of Elevidys voluntarily.Makary’s comments during an&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-18/fda-is-investigating-if-sarepta-s-elevidys-should-stay-on-market">interview</a> with Bloomberg come after the company on Thursday disclosed a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-draws-wall-street-ire-after-third-patient-death-this-year/ch8kMF7R5qY">third patient death</a> in a clinical trial involving a different experimental gene therapy that uses a similar viral delivery system.&nbsp;A company spokesperson&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-18/sarepta-says-another-patient-died-after-receiving-gene-therapy">told</a> Bloomberg that a 51-year-old patient died of acute liver failure last month in an early-stage trial of a gene therapy to treat limb-girdle muscular dystrophy.The FDA had already been investigating two earlier deaths linked to Elevidys.The growing number of fatalities is raising questions about the future of Sarepta’s therapies and the regulatory path for gene treatments that use adeno-associated viral (AAV) vectors. Elevidys, which was granted accelerated approval in 2023 for Duchenne muscular dystrophy, has remained on the market under post-approval study requirements.Bloomberg also reported that the latest death resulted in an unusually tense exchange between analysts and Sarepta executives on a Friday call. The same group of analysts reportedly had a call with the company earlier this week about the future of Elevidys, but the firm failed to disclose the third patient death. On Friday, two of the analysts asked executives whether the company was keeping any other fatalities undisclosed.“We are historically a very transparent organization,” said Sarepta CEO Douglas Ingram, according to the report, adding that the company didn’t disclose the third patient death earlier because “it was neither material nor central” to what was being discussed.&nbsp;Sarepta’s stock is down 88% year-to-date and nearly 90% over the past 12 months.Get updates to this developing story directly on Stocktwits.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/grubhub-owner-wonder-reportedly-in-talks-for-500-m-debt-refinancing/ch8kHoKR5qp">Grubhub Owner Wonder Reportedly In Talks For $500M Debt Refinancing</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

FDA Is Reportedly ‘Taking A Hard Look’ To Evaluate Whether Sarepta’s Gene Therapy Elevidys Should Remain On The Market

The FDA had already been investigating two earlier deaths linked to Elevidys.

IBB
iShares Biotechnology ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IBB News

IBBiShares Biotechnology ETF